Novel markers to predict virological and clinical relapse onset following antiviral treatment discontinuation in chronic hepatitis B patients
Translational Intelligence: On-Study Applications of Machine Learning to Integrated Biomarker and Clinical Data
February 12, 2021 — Integrating clinical and biomarker data enables both operational insights as well as scientific insights that can help teams make clinical trial decisions on-study.
Our last article defined the synthesis of these insights as translational intelligence, with the potential to illuminate key insights in drug development just as business intelligence is used to optimize business performance. We showed that, for example, having all the biomarker and clinical data linked together enables sponsors to quickly explore the relationship between drug response status and specific biomarkers of interest.
In this post, we further illustrate Read More →
Webinar On Demand: Critical On-Study Biomarker KPIs for Modern Trials – Part 2
Title: Critical On-Study Biomarker KPIs for Modern Trials – Part 2: Integrating Data Silos to Unlock Scientific Insights and Empower Translational Teams
Duration: 45 minutes
You will learn how to:
- Expand your use of exploratory biomarker data in combination with clinical metadata for on-study analytics
- Centralize integrated biomarker and clinical data as a single source of truth to expedite drug development decisions and enable translational exploration
- Leverage dashboards to support collaboration and quickly surface actionable insights
Translational Intelligence: Unlocking Insights from Expansive Biomarker Data
February 3, 2021 — In this brief, we explore Translational Intelligence – that is, navigating the vast biomarker data ecosystem to quickly uncover insights that would be missed by visual inspection alone, and which enable translational teams to focus on the right pathways, biological mechanisms, and / or patient populations.
